Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Sponsor: Kailera
Listed as NCT07284875, this observational or N/A phase trial focuses on Obesity and Overweight and remains actively recruiting participants. Sponsored by Kailera, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Mar 2026 — May 2026 [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Not Yet Recruiting PHASE3
First recorded
Dec 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Contact Information
- Kailera
For direct contact, visit the study record on ClinicalTrials.gov .